Zhu Katherine J, Lee Peter J, Austin Kirk K S, Solomon Michael J
Surgical Outcomes Research Centre (SOuRCe), Sydney Local Health District, University of Sydney, Sydney, Australia.
Department of Colorectal Surgery, Royal Prince Alfred Hospital, Institute of Academic Surgery, Sydney, Australia.
Dis Colon Rectum. 2019 Feb;62(2):196-202. doi: 10.1097/DCR.0000000000001249.
Ischiorectal fossa tumors are rare.
This study reviews a single institution's series of ischiorectal tumors with comparison against presacral tumors and assesses the utility of preoperative biopsy and angioembolization.
This is a retrospective study.
This study was conducted at a quaternary referral center.
All patients with ischiorectal tumor treated between February 1995 and April 2017 were retrospectively reviewed. Tumors extending secondarily into the ischiorectal fossa and inflammatory pathologies were excluded.
Preoperative biopsy, neoadjuvant therapy, angioembolization, and surgical excision of these tumors were reviewed.
Demographic, perioperative, pathological, and oncologic outcomes were evaluated.
Twenty-four patients (15 female; median age 54) were identified. Two-thirds were symptomatic. Forty-six percent had a palpable mass. All patients had CT and/or MRI. Fifty percent had a preoperative biopsy, of which 83% were diagnostic, and management was altered in 50%. All patients underwent surgical excision. Fifty-five percent had local excision, 38% had radical pelvic excision, and 8% had total mesorectal excision. Two patients had preoperative angioembolization. Both had successful R0 local excision. Morbidity occurred in 25%, with 1 major complication. There was no 30-day mortality. Histopathology demonstrated 17 soft tissue tumors (3 malignant), 2 GI stromal tumors, 1 neuroendocrine tumor, 1 Merkel cell carcinoma, 1 basaloid carcinoma, 1 epidermal cyst, and 1 lipoma. R0 resection was achieved in 75%. All patients were alive after a median follow-up of 33 months. Four patients developed recurrence at a median 10 months postoperatively. All recurrences were malignant, and 75% had had a R1 resection.
This study is limited by its small numbers. The quaternary institution source may introduce bias.
Ischiorectal fossa tumors are heterogeneous and more likely to be malignant than presacral tumors. Biopsy can be useful if a malignant diagnosis is suspected and changes management in 50% of cases. Preoperative embolization may be useful for large vascular tumors. R0 resection is important to minimize recurrence. See Video Abstract at http://links.lww.com/DCR/A779.
坐骨直肠窝肿瘤较为罕见。
本研究回顾了单一机构的一系列坐骨直肠窝肿瘤病例,并与骶前肿瘤进行比较,同时评估术前活检和血管栓塞的作用。
这是一项回顾性研究。
本研究在一家四级转诊中心进行。
对1995年2月至2017年4月期间接受治疗的所有坐骨直肠窝肿瘤患者进行回顾性分析。排除继发侵犯至坐骨直肠窝的肿瘤及炎性病变。
回顾这些肿瘤的术前活检、新辅助治疗、血管栓塞及手术切除情况。
评估人口统计学、围手术期、病理及肿瘤学结局。
共纳入24例患者(15例女性;中位年龄54岁)。三分之二的患者有症状。46%的患者可触及肿块。所有患者均行CT和/或MRI检查。50%的患者接受了术前活检,其中83%的活检结果具有诊断价值,50%的患者治疗方案因此改变。所有患者均接受了手术切除。55%的患者行局部切除,38%的患者行根治性盆腔切除,8%的患者行全直肠系膜切除。2例患者术前行血管栓塞。二者均成功实现R0局部切除。25%的患者出现并发症,其中1例为严重并发症。无30天内死亡病例。组织病理学检查显示17例软组织肿瘤(3例为恶性)、2例胃肠道间质瘤、1例神经内分泌肿瘤、1例默克尔细胞癌、1例基底样癌、1例表皮样囊肿及1例脂肪瘤。75%的患者实现了R0切除。中位随访33个月后,所有患者均存活。4例患者术后中位10个月出现复发。所有复发均为恶性,75%的复发患者为R1切除。
本研究受样本量小的限制。四级医疗机构来源可能存在偏倚。
坐骨直肠窝肿瘤具有异质性,比骶前肿瘤更易发生恶变。如果怀疑为恶性诊断,活检可能有用,且在50%的病例中可改变治疗方案。术前栓塞对大型血管性肿瘤可能有用。R0切除对于减少复发很重要。见视频摘要:http://links.lww.com/DCR/A779 。